Primary malignant melanoma of the genitourinary tract: case series of a rare form of primary mucosal melanoma.

IF 1 Q4 ONCOLOGY

Melanoma Management Pub Date : 2024-03-25 eCollection Date: 2024-02-01 DOI:10.2217/mmt-2023-0009

Olanrewaju Olapeju, Jonathan Shakesprere, Carie Boykin, Patrick Bacaj, Mohamad Salkini, Joanna Kolodney

引用次数: 0

Abstract

Primary malignant melanoma of the genitourinary tract is extremely rare. We present two such cases in elderly Caucasian females. An 81-year-old female with urinary retention and polypoid urinary bladder mass and a 72-year-old female with gross hematuria and urethral caruncle. After thorough evaluation, they were both eventually diagnosed with primary urogenital melanoma (SOX10 and MART1-positive in tumor cells). In both cases, the presence of melanoma-in-situ and absence of primary melanoma in other sites were consistent with primary urogenital melanoma. Immunotherapy with PD-1 inhibitors and use of neoadjuvant and adjuvant treatment are promising, as treatment guidelines remain unclear and overall survival is low. Additional clinical reporting of primary urogenital melanomas can help in better understanding and ultimately treating it.

查看原文本刊更多论文

泌尿生殖道原发性恶性黑色素瘤：罕见的原发性粘膜黑色素瘤病例系列。

泌尿生殖道原发性恶性黑色素瘤极为罕见。我们介绍了两例高加索老年女性的此类病例。一位是患有尿潴留和息肉样膀胱肿块的 81 岁女性，另一位是患有严重血尿和尿道痈的 72 岁女性。经过全面评估，她们最终都被确诊为原发性泌尿生殖系统黑色素瘤（肿瘤细胞中 SOX10 和 MART1 阳性）。在这两个病例中，原位黑色素瘤的存在和其他部位原发性黑色素瘤的缺失与原发性泌尿生殖器黑色素瘤一致。使用PD-1抑制剂进行免疫治疗以及采用新辅助治疗和辅助治疗是很有希望的，因为治疗指南仍不明确，总生存率也很低。更多有关原发性泌尿生殖器黑色素瘤的临床报告有助于更好地了解并最终治疗这种疾病。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Melanoma Management ONCOLOGY-

CiteScore

5.10

自引率

0.00%

发文量

审稿时长

13 weeks

期刊介绍： Skin cancer is on the rise. According to the World Health Organization, 132,000 melanoma skin cancers occur globally each year. While early-stage melanoma is usually relatively easy to treat, once disease spreads prognosis worsens considerably. Therefore, research into combating advanced-stage melanoma is a high priority. New and emerging therapies, such as monoclonal antibodies, B-RAF and KIT inhibitors, antiangiogenic agents and novel chemotherapy approaches hold promise for prolonging survival, but the search for a cure is ongoing. Melanoma Management publishes high-quality peer-reviewed articles on all aspects of melanoma, from prevention to diagnosis and from treatment of early-stage disease to late-stage melanoma and metastasis. The journal presents the latest research findings in melanoma research and treatment, together with authoritative reviews, cutting-edge editorials and perspectives that highlight hot topics and controversy in the field. Independent drug evaluations assess newly approved medications and their role in clinical practice. Key topics covered include: Risk factors, prevention and sun safety education Diagnosis, staging and grading Surgical excision of melanoma lesions Sentinel lymph node biopsy Biological therapies, including immunotherapy and vaccination Novel chemotherapy options Treatment of metastasis Prevention of recurrence Patient care and quality of life.